GSK has unveiled positive data from its Phase III AReSVi-006 clinical trial of Arexvy, its RSV vaccine, which aims to prevent lower respiratory tract disease (LRTD) over three RSV seasons.

Read also

Myeloma

Myeloma treatment HDP-101 put on FDA fast track

Evotec Announces Progress

Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb

Evotec Announces Progress

Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb

Tylenol (paracetamol)

Tylenol (paracetamol) fights autism claims, slams proposed FDA warning label as 'unsupported' by science